CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

Study Summary

This study will find out if a new medicine called NNC6019-0001 can help reduce the risk of heart-related death and illness in participants with a condition called transthyretin amyloid cardiomyopathy (ATTR-CM), which affects the heart. Participants will either receive NNC6019-0001 or a placebo (a treatment with no active medicine), and which one they get is decided by chance. Everyone in the study will continue receiving their usual heart treatments as recommended by their doctor.

Conditions

Transthyretin Amyloid Cardiomyopathy (ATTR CM)

Interventions / Drugs

NNC6019-0001 Placebo (NNC6019-0001)

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment1280 participants

Primary Completion—

Lead SponsorNovo Nordisk A/S

Data Retrieved2026-04-11 02:55:47.366980+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.